Investigating the role of mutant p53 and MCL-1 in the sustained growth of MYC lymphomas and strategies for targeted therapy

研究突变型p53和MCL-1在MYC淋巴瘤持续生长中的作用及靶向治疗策略

• 批准号: nhmrc : 1086291
• 负责人: Dr Gemma Kelly
• 金额: $ 41.14万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/investigating-role-mutant-targeted-therapy/519127
• 关键词: Investigating; role; mutant; p53; MCL

A large number of human cancers have abnormal expression of a protein called MYC, leading to rapid growth. We found that when another protein called MCL-1 was inactivated, the lymphomas regressed. Importantly, mutations in the tumour suppressor gene called p53 are frequently found in cancer cells and we noticed that this could reduce the dependency on MCL-1. We aim to investigate this further in this grant proposal, in part using a novel drug that targets MCL-1.

大量的人类癌症都有一种叫做MYC的蛋白质的异常表达，导致快速生长。我们发现，当另一种称为MCL-1的蛋白质失活时，淋巴瘤会消退。重要的是，在癌细胞中经常发现称为p53的肿瘤抑制基因的突变，我们注意到这可以减少对MCL-1的依赖。我们的目标是在这项拨款提案中进一步研究这一点，部分使用一种靶向MCL-1的新药。